Japan Lifeline (7575) Q2 2027 earnings summary

Executive summary

• H1 FY2027 net sales set a six-month record at ¥31,353mn, up 7.1% YoY; operating profit fell 17.4% to ¥5,468mn and net income fell 7.2% to ¥4,430mn.

• EP/Ablation and newer Neurovascular and Gastrointestinal businesses offset lower CRM sales; higher R&D and other SG&A weighed on profit.

Financial highlights

• H1 net sales rose ¥2,068mn to ¥31,353mn; proprietary products grew 11.0% YoY and procured products 2.0%.

• Gross profit increased 2.6% to ¥18,018mn, while SG&A rose 14.8% to ¥12,550mn; operating profit declined to ¥5,468mn.

• Q2 sales set a record at ¥15,449mn, up 5.3% YoY; operating profit fell 25.2% to ¥2,502mn and net income fell 14.2% to ¥2,120mn.

• Ordinary profit decreased 8.8% to ¥6,040mn; non-operating income included a ¥367mn securities valuation gain and ¥203mn bad-debt allowance reversal, while extraordinary income included a ¥346mn securities-sale gain.

• Basic EPS was ¥63.15 versus ¥68.08 YoY; comprehensive income was ¥4,254mn versus ¥4,667mn.

Outlook and guidance

• FY2027 guidance unchanged: net sales ¥63,200mn, operating profit ¥10,700mn, ordinary profit ¥10,800mn and net income ¥8,000mn; H1 attained 49.6%, 51.1%, 55.9% and 55.4%, respectively.

• H1 profit exceeded plan mainly because R&D expenses were delayed; most are expected from Q3 onward, with full-year profit generally expected to remain in line with guidance.

• Management expects sales generally in line with guidance from Q3 onward; CRM weakness is expected to continue, while EP/Ablation, Neurovascular and Gastrointestinal sales are expected to expand.

• FY2028 mid-term plan forecast is ¥68.0bn sales and ¥7.0bn operating profit, below targets of ¥70.0bn and ¥11.0bn; cited factors include delayed TAVI launch and accelerated R&D investment.